Skip to main content
Erschienen in: Journal of Bone and Mineral Metabolism 4/2010

01.07.2010 | Perspective

Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons

verfasst von: Toshiyuki Yoneda, Hiroshi Hagino, Toshitsugu Sugimoto, Hiroaki Ohta, Shunji Takahashi, Satoshi Soen, Akira Taguchi, Satoru Toyosawa, Toshihiko Nagata, Masahiro Urade

Erschienen in: Journal of Bone and Mineral Metabolism | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Bisphosphonates (BPs) have been widely, efficiently, and safely used for the treatment of osteoporosis, malignant hypercalcemia, bone metastasis of solid cancers, and multiple myeloma bone diseases. Accumulating recent reports describe that surgical dental treatments in patients with cancer or osteoporosis who have been receiving intravenous or oral BPs are associated with osteonecrosis of the jaw (bisphosphonate-related osteonecrosis of the jaw, BRONJ). The accurate incidence, clinical backgrounds, and pathogenesis of BRONJ have been unclear and appropriate approaches for prevention and treatment have not been established to date. To address the current situation of BRONJ in Japan, the “Allied Task Force Committee of Bisphosphonate-Related Osteonecrosis of the Jaw,” consisting of physicians specializing in bone biology, orthopedic surgery, rheumatology, obstetrics/gynecology, and medical oncology and dentists specializing in oral surgery, periodontology, dental radiology, and oral pathology, was organized. The committee attempted to propose a standard position paper for the treatment of BRONJ. The committee expects that this proposal will provide objective and correct scientific information on BRONJ and will serve as a reference for conducting dental procedures for patients receiving BPs and in designing prevention and treatment of BRONJ. However, because this position paper is not based on direct clinical evidence, it should be used as a reference, and a decision on treatment in each case should be made after an extensive discussion among physicians, dentists/oral surgeons, and the patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Phipps RJ, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebetino FH (2007) Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 1117:209–257CrossRefPubMed Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Phipps RJ, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebetino FH (2007) Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 1117:209–257CrossRefPubMed
2.
Zurück zum Zitat McCauley LK, Li X (2007) Distinguishing features of the oral cavity and its predisposition to osteonecrosis. J Musculoskelet Neuronal Interact 7:356–357PubMed McCauley LK, Li X (2007) Distinguishing features of the oral cavity and its predisposition to osteonecrosis. J Musculoskelet Neuronal Interact 7:356–357PubMed
3.
Zurück zum Zitat Marx RE, Cillo JE Jr, Ulloa JJ (2007) Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65:2397–2410CrossRefPubMed Marx RE, Cillo JE Jr, Ulloa JJ (2007) Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65:2397–2410CrossRefPubMed
4.
Zurück zum Zitat Huja SS, Beck FM (2008) Bone remodeling in maxilla, mandible, and femur of young dogs. Anat Rec 291:1–5CrossRef Huja SS, Beck FM (2008) Bone remodeling in maxilla, mandible, and femur of young dogs. Anat Rec 291:1–5CrossRef
5.
Zurück zum Zitat Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws (2007) American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65:369–376 Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws (2007) American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65:369–376
6.
Zurück zum Zitat Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, American Association of Oral, Maxillofacial Surgeons (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws–2009 update. J Oral Maxillofac Surg 67(5 Suppl):2–12PubMed Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, American Association of Oral, Maxillofacial Surgeons (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws–2009 update. J Oral Maxillofac Surg 67(5 Suppl):2–12PubMed
7.
Zurück zum Zitat Otto S, Hafner S, Grötz KA (2009) The role of inferior alveolar nerve involvement in bisphosphonate-related osteonecrosis of the jaw. J Oral Maxillofac Surg 67:589–592CrossRefPubMed Otto S, Hafner S, Grötz KA (2009) The role of inferior alveolar nerve involvement in bisphosphonate-related osteonecrosis of the jaw. J Oral Maxillofac Surg 67:589–592CrossRefPubMed
8.
Zurück zum Zitat Assael LA (2009) Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies. J Oral Maxillofac Surg 67(5 Suppl):35–43CrossRefPubMed Assael LA (2009) Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies. J Oral Maxillofac Surg 67(5 Suppl):35–43CrossRefPubMed
9.
Zurück zum Zitat Nusair YM, Younis MH (2007) Prevalence, clinical picture, and risk factors of dry socket in a Jordanian dental teaching center. J Contemp Dent Pract 8:53–63PubMed Nusair YM, Younis MH (2007) Prevalence, clinical picture, and risk factors of dry socket in a Jordanian dental teaching center. J Contemp Dent Pract 8:53–63PubMed
10.
Zurück zum Zitat Woo SB, Hellstein JW, Kalmar JR (2006) Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753–761PubMed Woo SB, Hellstein JW, Kalmar JR (2006) Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753–761PubMed
11.
Zurück zum Zitat Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23:826–836CrossRefPubMed Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23:826–836CrossRefPubMed
12.
Zurück zum Zitat Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS (2007) Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst 99:1016–1024CrossRefPubMed Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS (2007) Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst 99:1016–1024CrossRefPubMed
13.
Zurück zum Zitat Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G (2008) Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 44:857–869CrossRefPubMed Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G (2008) Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 44:857–869CrossRefPubMed
14.
Zurück zum Zitat Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580–8587CrossRefPubMed Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580–8587CrossRefPubMed
15.
Zurück zum Zitat Estefania Fresco R, Ponte Fernandez R, Aguirre Urizar JM (2006) Bisphosphonates and oral pathology II. Osteonecrosis of the jaws: review of the literature before 2005. Med Oral Patol Oral Cir Bucal 11:E456–E461PubMed Estefania Fresco R, Ponte Fernandez R, Aguirre Urizar JM (2006) Bisphosphonates and oral pathology II. Osteonecrosis of the jaws: review of the literature before 2005. Med Oral Patol Oral Cir Bucal 11:E456–E461PubMed
16.
Zurück zum Zitat Durie BG, Katz M, Crowley J (2005) Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353:99–102CrossRefPubMed Durie BG, Katz M, Crowley J (2005) Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353:99–102CrossRefPubMed
17.
Zurück zum Zitat Maerevoet M, Martin C, Duck L (2005) Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353:99–102CrossRefPubMed Maerevoet M, Martin C, Duck L (2005) Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353:99–102CrossRefPubMed
18.
Zurück zum Zitat Mavrokokki T, Cheng A, Stein B, Goss A (2007) Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65:415–423CrossRefPubMed Mavrokokki T, Cheng A, Stein B, Goss A (2007) Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65:415–423CrossRefPubMed
19.
Zurück zum Zitat Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S et al (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679–691CrossRefPubMed Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S et al (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679–691CrossRefPubMed
20.
Zurück zum Zitat Brufsky AM, Bosserman LD, Caradonna RR, Haley BB, Jones CM, Moore HC, Jin L, Warsi GM, Ericson SG, Perez EA (2009) Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 9:77–85CrossRefPubMed Brufsky AM, Bosserman LD, Caradonna RR, Haley BB, Jones CM, Moore HC, Jin L, Warsi GM, Ericson SG, Perez EA (2009) Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 9:77–85CrossRefPubMed
21.
Zurück zum Zitat Grbic JT, Landesberg R, Lin SO, Mesenbrink P, Teid IR, Leung PC, Casas N, Recknor CP, Hua Y, Delmas PD, Eriksen EF (2008) Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yeary pivotal fracture trial. J Am Dent Assoc 139:32–40PubMed Grbic JT, Landesberg R, Lin SO, Mesenbrink P, Teid IR, Leung PC, Casas N, Recknor CP, Hua Y, Delmas PD, Eriksen EF (2008) Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yeary pivotal fracture trial. J Am Dent Assoc 139:32–40PubMed
22.
Zurück zum Zitat Felsenberg D, Hoffmeister B, Amling M, Seibel MJ, Fratzl P (2006) Kiefernekrosen nach hoch dosierter bisphosphonattherapie. Dtsch Arzebl 103:3078–3081 Felsenberg D, Hoffmeister B, Amling M, Seibel MJ, Fratzl P (2006) Kiefernekrosen nach hoch dosierter bisphosphonattherapie. Dtsch Arzebl 103:3078–3081
23.
Zurück zum Zitat Edwards BJ, Hellstein JW, Jacobsen PL, Kaltman S, Mariotti A, Migliorati CA (2008) American Dental Association Council on Scientific Affairs Expert Panel on Bisphosphonate-Associated Osteonecrosis of the Jaw. Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 139:1674–1677PubMed Edwards BJ, Hellstein JW, Jacobsen PL, Kaltman S, Mariotti A, Migliorati CA (2008) American Dental Association Council on Scientific Affairs Expert Panel on Bisphosphonate-Associated Osteonecrosis of the Jaw. Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 139:1674–1677PubMed
24.
Zurück zum Zitat Phal PM, Myall RW, Assael LA, Weissman JL (2007) Imaging findings of bisphosphonate-associated osteonecrosis of the jaws. AJNR Am J Neuroradiol 28:1139–1145CrossRefPubMed Phal PM, Myall RW, Assael LA, Weissman JL (2007) Imaging findings of bisphosphonate-associated osteonecrosis of the jaws. AJNR Am J Neuroradiol 28:1139–1145CrossRefPubMed
25.
Zurück zum Zitat Marx RE (2006) Oral and intravenous bisphosphonate-induced osteonecrosis of the jaws: history, etiology, prevention, and treatment. Quintessence Publishing, Carol Stream, IL Marx RE (2006) Oral and intravenous bisphosphonate-induced osteonecrosis of the jaws: history, etiology, prevention, and treatment. Quintessence Publishing, Carol Stream, IL
26.
Zurück zum Zitat Chiandussi S, Biasotto M, Dore F, Cavalli F, Cova MA, Di Lenarda R (2006) Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dentomaxillofac Radiol 35:236–243CrossRefPubMed Chiandussi S, Biasotto M, Dore F, Cavalli F, Cova MA, Di Lenarda R (2006) Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dentomaxillofac Radiol 35:236–243CrossRefPubMed
27.
Zurück zum Zitat Bianchi SD, Scoletta M, Cassione FB, Migliaretti G, Mozzati M (2007) Computerized tomographic findings in bisphosphonate-associated osteonecrosis of the jaw in patients with cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 104:249–258CrossRefPubMed Bianchi SD, Scoletta M, Cassione FB, Migliaretti G, Mozzati M (2007) Computerized tomographic findings in bisphosphonate-associated osteonecrosis of the jaw in patients with cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 104:249–258CrossRefPubMed
28.
Zurück zum Zitat Raje N, Woo SB, Hande K, Yap JT, Richardson PG et al (2008) Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res 14:2387–2395CrossRefPubMed Raje N, Woo SB, Hande K, Yap JT, Richardson PG et al (2008) Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res 14:2387–2395CrossRefPubMed
29.
Zurück zum Zitat Treister N, Sheehy N, Bae EH, Friedland B, Lerman M, Woo S (2009) Dental panoramic radiographic evaluation in bisphosphonate-associated osteonecrosis of the jaws. Oral Dis 15:88–92CrossRefPubMed Treister N, Sheehy N, Bae EH, Friedland B, Lerman M, Woo S (2009) Dental panoramic radiographic evaluation in bisphosphonate-associated osteonecrosis of the jaws. Oral Dis 15:88–92CrossRefPubMed
30.
Zurück zum Zitat Bedogni A, Blandamura S, Lokmic Z, Palumbo C, Ragazzo M, Ferrari F, Tregnaghi A, Pietrogrande F, Procopio O, Saia G, Ferretti M, Bedogni G, Chiarini L, Ferronato G, Ninfo V, Lo Russo L, Lo Muzio L, Nocini PF (2008) Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 105:358–364CrossRefPubMed Bedogni A, Blandamura S, Lokmic Z, Palumbo C, Ragazzo M, Ferrari F, Tregnaghi A, Pietrogrande F, Procopio O, Saia G, Ferretti M, Bedogni G, Chiarini L, Ferronato G, Ninfo V, Lo Russo L, Lo Muzio L, Nocini PF (2008) Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 105:358–364CrossRefPubMed
31.
Zurück zum Zitat Bisdas S, Chambron Pinho N, Smolarz A, Sader R, Vogl TJ, Mack MG (2008) Biphosphonate-induced osteonecrosis of the jaws: CT and MRI spectrum of findings in 32 patients. Clin Radiol 63:71–77CrossRefPubMed Bisdas S, Chambron Pinho N, Smolarz A, Sader R, Vogl TJ, Mack MG (2008) Biphosphonate-induced osteonecrosis of the jaws: CT and MRI spectrum of findings in 32 patients. Clin Radiol 63:71–77CrossRefPubMed
32.
Zurück zum Zitat Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR et al (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479–1491CrossRefPubMed Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR et al (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479–1491CrossRefPubMed
33.
Zurück zum Zitat Mawardi H, Treister N, Richardson P, Anderson K, Munshi N, Faiella RA, Woo SB (2009) Sinus tracts—an early sign of bisphosphonate-associated osteonecrosis of the jaws? J Oral Maxillofac Surg 67:593–601CrossRefPubMed Mawardi H, Treister N, Richardson P, Anderson K, Munshi N, Faiella RA, Woo SB (2009) Sinus tracts—an early sign of bisphosphonate-associated osteonecrosis of the jaws? J Oral Maxillofac Surg 67:593–601CrossRefPubMed
34.
Zurück zum Zitat Garcia-Ferrer L, Bagin JV, Martinez-Sanjuan V, Hernandez-Bazan S, Garcia R, Jiminez-Soriano Y, Hervas V (2008) MRI of mandibular osteonecrosis secondary to bisphosphonates. AJR Am J Roentgenol 190:949–955CrossRefPubMed Garcia-Ferrer L, Bagin JV, Martinez-Sanjuan V, Hernandez-Bazan S, Garcia R, Jiminez-Soriano Y, Hervas V (2008) MRI of mandibular osteonecrosis secondary to bisphosphonates. AJR Am J Roentgenol 190:949–955CrossRefPubMed
35.
Zurück zum Zitat Zanglis A, Andreopoulos D, Dima M, Baltas G, Baziotis N (2007) Jaw uptake of technetium-99 methylene diphosphonate in patients on biphosphonates: a word of caution. Hell J Nucl Med 10:177–180PubMed Zanglis A, Andreopoulos D, Dima M, Baltas G, Baziotis N (2007) Jaw uptake of technetium-99 methylene diphosphonate in patients on biphosphonates: a word of caution. Hell J Nucl Med 10:177–180PubMed
36.
Zurück zum Zitat O’Ryan FS, Khoury S, Liao W, Han MM, Hui RL, Baer D, Martin D, Liberty D, Lo JC (2009) Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. J Oral Maxillofac Surg 67:1363–1372CrossRefPubMed O’Ryan FS, Khoury S, Liao W, Han MM, Hui RL, Baer D, Martin D, Liberty D, Lo JC (2009) Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. J Oral Maxillofac Surg 67:1363–1372CrossRefPubMed
37.
Zurück zum Zitat Ho L, Quan V, Henderson R (2008) Zoledronate-related osteonecrosis of the mandible. Clin Nucl Med 33:68–70CrossRefPubMed Ho L, Quan V, Henderson R (2008) Zoledronate-related osteonecrosis of the mandible. Clin Nucl Med 33:68–70CrossRefPubMed
38.
Zurück zum Zitat Krishnan A, Arslanoglu A, Yildirm N, Silbergleit R, Aygun N (2009) Imaging findings of bisphosphonate-related osteonecrosis of the jaw with emphasis on early magnetic resonance imaging findings. J Comput Assist Tomogr 33:298–304CrossRefPubMed Krishnan A, Arslanoglu A, Yildirm N, Silbergleit R, Aygun N (2009) Imaging findings of bisphosphonate-related osteonecrosis of the jaw with emphasis on early magnetic resonance imaging findings. J Comput Assist Tomogr 33:298–304CrossRefPubMed
39.
Zurück zum Zitat Hansen T, Kunkel M, Weber A, James Kirkpatrick C (2006) Osteonecrosis of the jaws in patients treated with bisphosphonates: histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 35:155–160CrossRefPubMed Hansen T, Kunkel M, Weber A, James Kirkpatrick C (2006) Osteonecrosis of the jaws in patients treated with bisphosphonates: histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 35:155–160CrossRefPubMed
40.
Zurück zum Zitat Dodson TB, Raje NS, Caruso PA, Rosenberg AE (2008) Case records of the Massachusetts General Hospital Case 9–2008. A 65-year-old woman with a nonhealing ulcer of the jaw. N Engl J Med 358:1283–1291CrossRefPubMed Dodson TB, Raje NS, Caruso PA, Rosenberg AE (2008) Case records of the Massachusetts General Hospital Case 9–2008. A 65-year-old woman with a nonhealing ulcer of the jaw. N Engl J Med 358:1283–1291CrossRefPubMed
41.
Zurück zum Zitat Kim HK (2007) Introduction to osteonecrosis of the femoral head (OFH) and osteonecrosis of the jaw (ONJ). J Musculoskelet Neuronal Interact 7:350–353PubMed Kim HK (2007) Introduction to osteonecrosis of the femoral head (OFH) and osteonecrosis of the jaw (ONJ). J Musculoskelet Neuronal Interact 7:350–353PubMed
42.
Zurück zum Zitat Bertoldo F, Santini D, Lo Cascio V (2007) Bisphosphonates, osteomyelitis of the jaw: a pathogenic puzzle. Nat Clin Pract Oncol 4:711–721CrossRefPubMed Bertoldo F, Santini D, Lo Cascio V (2007) Bisphosphonates, osteomyelitis of the jaw: a pathogenic puzzle. Nat Clin Pract Oncol 4:711–721CrossRefPubMed
43.
Zurück zum Zitat Hansen T, Kunkel M, Springer E, Walter C, Weber A, Siegel E, Kirkpatrick CJ (2007) Actinomycosis of the jaws—histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis. Virchows Arch 451:1009–1017CrossRefPubMed Hansen T, Kunkel M, Springer E, Walter C, Weber A, Siegel E, Kirkpatrick CJ (2007) Actinomycosis of the jaws—histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis. Virchows Arch 451:1009–1017CrossRefPubMed
44.
Zurück zum Zitat Hansen T, Kirkpatrick CJ, Walter C, Kunkel M (2006) Increased numbers of osteoclasts expressing cysteine proteinase cathepsin K in patients with infected osteoradionecrosis and bisphosphonate-associated osteonecrosis: a paradoxical observation? Virchows Arch 449:448–454 Hansen T, Kirkpatrick CJ, Walter C, Kunkel M (2006) Increased numbers of osteoclasts expressing cysteine proteinase cathepsin K in patients with infected osteoradionecrosis and bisphosphonate-associated osteonecrosis: a paradoxical observation? Virchows Arch 449:448–454
45.
Zurück zum Zitat Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339:292–299CrossRefPubMed Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339:292–299CrossRefPubMed
46.
Zurück zum Zitat Favio G, Piilloli GP, Maiorano E (2009) Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy. Bone (NY) 45:406–413 Favio G, Piilloli GP, Maiorano E (2009) Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy. Bone (NY) 45:406–413
47.
Zurück zum Zitat Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, Clezardin P (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62:6538–6544PubMed Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, Clezardin P (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62:6538–6544PubMed
48.
Zurück zum Zitat Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M, Salerno A, Denaro V, Tonini G (2002) Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 8:1080–1084PubMed Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M, Salerno A, Denaro V, Tonini G (2002) Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 8:1080–1084PubMed
49.
Zurück zum Zitat Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115–1117CrossRefPubMed Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115–1117CrossRefPubMed
50.
Zurück zum Zitat Hoefert S, Schmitz I, Tannapfel A, Eufinger H (2009) Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. Clin Oral Invest (in press) Hoefert S, Schmitz I, Tannapfel A, Eufinger H (2009) Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. Clin Oral Invest (in press)
51.
Zurück zum Zitat Hazenberg JG, Freeley M, Foran E, Lee TC, Taylor D (2006) Microdamage: a cell-transducing mechanism based on ruptured osteocyte processes. J Biomech 39:2096–2103CrossRefPubMed Hazenberg JG, Freeley M, Foran E, Lee TC, Taylor D (2006) Microdamage: a cell-transducing mechanism based on ruptured osteocyte processes. J Biomech 39:2096–2103CrossRefPubMed
52.
Zurück zum Zitat Baim S, Miller PD (2009) Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res 24:561–574CrossRefPubMed Baim S, Miller PD (2009) Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res 24:561–574CrossRefPubMed
53.
Zurück zum Zitat Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR et al (2008) Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 66:1320–1321CrossRefPubMed Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR et al (2008) Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 66:1320–1321CrossRefPubMed
54.
Zurück zum Zitat Lehrer S, Montazem A, Ramanathan L, Pessin-Minsley M, Pfail J, Stock RG, Kogan R (2008) Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 67:159–161 Lehrer S, Montazem A, Ramanathan L, Pessin-Minsley M, Pfail J, Stock RG, Kogan R (2008) Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 67:159–161
55.
Zurück zum Zitat Fantasia JE (2009) Bisphosphonates—what the dentist needs to know: practical considerations. J Oral Maxillofac Surg 67(5 Suppl):53–60CrossRefPubMed Fantasia JE (2009) Bisphosphonates—what the dentist needs to know: practical considerations. J Oral Maxillofac Surg 67(5 Suppl):53–60CrossRefPubMed
56.
Zurück zum Zitat Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, Fenton R, Gahres N, Sausville E, Ord R, Meiller T (2006) Osteonecrosis of the jaw in multiple myeloma patients. Clinical features and risk factors. J Clin Oncol 24:945–952CrossRefPubMed Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, Fenton R, Gahres N, Sausville E, Ord R, Meiller T (2006) Osteonecrosis of the jaw in multiple myeloma patients. Clinical features and risk factors. J Clin Oncol 24:945–952CrossRefPubMed
57.
Zurück zum Zitat Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527–534CrossRefPubMed Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527–534CrossRefPubMed
58.
Zurück zum Zitat Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567–1575CrossRefPubMed Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567–1575CrossRefPubMed
59.
Zurück zum Zitat Jeffcoat MK (2006) Safety of oral bisphosphonates: controlled studies on alveolar bone. Int J Oral Maxillofac Implants 21:349–353PubMed Jeffcoat MK (2006) Safety of oral bisphosphonates: controlled studies on alveolar bone. Int J Oral Maxillofac Implants 21:349–353PubMed
60.
Zurück zum Zitat Bell BM, Bell RE (2008) Oral bisphosphonates and dental implants: a retrospective study. J Oral Maxillofac Surg 66:1022–1024CrossRefPubMed Bell BM, Bell RE (2008) Oral bisphosphonates and dental implants: a retrospective study. J Oral Maxillofac Surg 66:1022–1024CrossRefPubMed
61.
Zurück zum Zitat Grant BT, Amenedo C, Freeman K, Kraut RA (2008) Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases. J Oral Maxillofac Surg 66:223–230CrossRefPubMed Grant BT, Amenedo C, Freeman K, Kraut RA (2008) Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases. J Oral Maxillofac Surg 66:223–230CrossRefPubMed
62.
Zurück zum Zitat Khamaisi M, Regev E, Yarom N, Avni B, Leitersdorf E, Raz I, Elad S (2007) Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab 92:1172–1175CrossRefPubMed Khamaisi M, Regev E, Yarom N, Avni B, Leitersdorf E, Raz I, Elad S (2007) Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab 92:1172–1175CrossRefPubMed
63.
Zurück zum Zitat Wessel JH, Dodson TB, Zavras AI (2008) Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 66:625–631CrossRefPubMed Wessel JH, Dodson TB, Zavras AI (2008) Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 66:625–631CrossRefPubMed
64.
Zurück zum Zitat Lehrer S, Montazem A, Ramanathan L, Pessin-Minsley M, Pfail J, Stock RG, Kogan R (2009) Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene. J Oral Maxillofac Surg 67:159–161CrossRefPubMed Lehrer S, Montazem A, Ramanathan L, Pessin-Minsley M, Pfail J, Stock RG, Kogan R (2009) Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene. J Oral Maxillofac Surg 67:159–161CrossRefPubMed
65.
Zurück zum Zitat Sarasquete ME, Garcia-Sanz R, Marin L, Alcoceba M, Chillon MC, Balanzategui A, Santamaria C, Rosinol L, de la Rubia J, Hernandez MT, Garcia-Navarro I, Lahuerta JJ, Gonzalez M, San Miguel JF (2008) Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 112:2709–2712CrossRefPubMed Sarasquete ME, Garcia-Sanz R, Marin L, Alcoceba M, Chillon MC, Balanzategui A, Santamaria C, Rosinol L, de la Rubia J, Hernandez MT, Garcia-Navarro I, Lahuerta JJ, Gonzalez M, San Miguel JF (2008) Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 112:2709–2712CrossRefPubMed
66.
Zurück zum Zitat Ficarra G, Beninati F, Rubino I, Vannucchi A, Longo G, Tonelli P, Pini Prato G (2005) Osteonecrosis of the jaw in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol 32:1123–1128CrossRefPubMed Ficarra G, Beninati F, Rubino I, Vannucchi A, Longo G, Tonelli P, Pini Prato G (2005) Osteonecrosis of the jaw in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol 32:1123–1128CrossRefPubMed
67.
Zurück zum Zitat Sarathy AP, Bourgeois SL Jr, Goodell GG (2005) Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports. J Endod 31:759–763CrossRefPubMed Sarathy AP, Bourgeois SL Jr, Goodell GG (2005) Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports. J Endod 31:759–763CrossRefPubMed
68.
Zurück zum Zitat Migliorati CA, Siegel MA, Elting LS (2006) Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 7:508–514CrossRefPubMed Migliorati CA, Siegel MA, Elting LS (2006) Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 7:508–514CrossRefPubMed
69.
Zurück zum Zitat Palomo L, Bissada N, Liu J (2006) Bisphosphonate therapy for bone loss in patients with osteoporosis and periodontal disease: clinical perspectives and review of the literature. Quintessence Int 37:103–107PubMed Palomo L, Bissada N, Liu J (2006) Bisphosphonate therapy for bone loss in patients with osteoporosis and periodontal disease: clinical perspectives and review of the literature. Quintessence Int 37:103–107PubMed
70.
Zurück zum Zitat Dodson TB (2009) Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 67(5 Suppl):44–52CrossRefPubMed Dodson TB (2009) Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 67(5 Suppl):44–52CrossRefPubMed
71.
Zurück zum Zitat Soileau KM (2006) Oral post-surgical complications following the administration of bisphosphonates given for osteopenia related to malignancy. J Periodontol 77:738–743CrossRefPubMed Soileau KM (2006) Oral post-surgical complications following the administration of bisphosphonates given for osteopenia related to malignancy. J Periodontol 77:738–743CrossRefPubMed
72.
Zurück zum Zitat Khan AA, Sandor GK, Dore E, Morrison AD, Alsahli M et al (2008) Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 35:1391–1397PubMed Khan AA, Sandor GK, Dore E, Morrison AD, Alsahli M et al (2008) Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 35:1391–1397PubMed
73.
Zurück zum Zitat Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, Grbic J, Jontell M, Landesberg R, Laslop A, Wollenhaupt M, Papapoulos S, Sezer O, Sprafka M, Reginster JY (2008) Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone (NY) 42:841–847 Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, Grbic J, Jontell M, Landesberg R, Laslop A, Wollenhaupt M, Papapoulos S, Sezer O, Sprafka M, Reginster JY (2008) Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone (NY) 42:841–847
74.
Zurück zum Zitat Dannemann C, Grtz KW, Riener MO, Zwahlen RA (2007) Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder. Bone (NY) 40:828–834 Dannemann C, Grtz KW, Riener MO, Zwahlen RA (2007) Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder. Bone (NY) 40:828–834
75.
Zurück zum Zitat Allen MR, Burr DB (2009) The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 67(5 Suppl):61–70CrossRefPubMed Allen MR, Burr DB (2009) The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 67(5 Suppl):61–70CrossRefPubMed
76.
Zurück zum Zitat Sedghizadeh PP, Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW (2008) Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J Oral Maxillofac Surg 66:767–775CrossRefPubMed Sedghizadeh PP, Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW (2008) Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J Oral Maxillofac Surg 66:767–775CrossRefPubMed
77.
Zurück zum Zitat Kobayashi Y, Hiraga T, Ueda A, Wang L, Matsumoto-Nakano M, Hata K, Yatani H, Yoneda T (2010) Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, with causing no osteonecrosis of the jaw in mice. J Bone Miner Metab (in press) Kobayashi Y, Hiraga T, Ueda A, Wang L, Matsumoto-Nakano M, Hata K, Yatani H, Yoneda T (2010) Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, with causing no osteonecrosis of the jaw in mice. J Bone Miner Metab (in press)
78.
Zurück zum Zitat Wood J, Bonjean K, Ruetz S, Bellahcène A, Devy L, Foidart JM, Castronovo V, Green JR (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302:1055–1061CrossRefPubMed Wood J, Bonjean K, Ruetz S, Bellahcène A, Devy L, Foidart JM, Castronovo V, Green JR (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302:1055–1061CrossRefPubMed
79.
Zurück zum Zitat Estilo CL, Fornier M, Farooki A, Carlson D, Bohle G 3rd, Huryn JM (2008) Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 26:4037–4038CrossRefPubMed Estilo CL, Fornier M, Farooki A, Carlson D, Bohle G 3rd, Huryn JM (2008) Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 26:4037–4038CrossRefPubMed
80.
Zurück zum Zitat Reid IR, Bolland MJ, Grey AB (2007) Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone (NY) 41:318–320 Reid IR, Bolland MJ, Grey AB (2007) Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone (NY) 41:318–320
81.
Zurück zum Zitat Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinha S, Garrett-Sinha L, Raghavan S (2008) Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 66:839–847CrossRefPubMed Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinha S, Garrett-Sinha L, Raghavan S (2008) Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 66:839–847CrossRefPubMed
82.
Zurück zum Zitat Reid IR (2009) Osteonecrosis of the jaw: who gets it, and why? Bone (NY) 44:4–10 Reid IR (2009) Osteonecrosis of the jaw: who gets it, and why? Bone (NY) 44:4–10
83.
Zurück zum Zitat Allen MR, Burr DB (2008) Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg 66:987–994CrossRefPubMed Allen MR, Burr DB (2008) Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg 66:987–994CrossRefPubMed
84.
Zurück zum Zitat Sonis ST, Watkins BA, Lyng GD, Lerman MA, Anderson KC (2009) Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol 45:164–172CrossRefPubMed Sonis ST, Watkins BA, Lyng GD, Lerman MA, Anderson KC (2009) Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol 45:164–172CrossRefPubMed
85.
Zurück zum Zitat Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, Bareggi C, Ascani L, Cislaghi E (2009) Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20:137–145CrossRefPubMed Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, Bareggi C, Ascani L, Cislaghi E (2009) Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20:137–145CrossRefPubMed
86.
Zurück zum Zitat Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, Migkou M, Eleftherakis-Papaiakovou E, Christoulas D, Terpos E, Bamias A (2009) Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20:117–120CrossRefPubMed Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, Migkou M, Eleftherakis-Papaiakovou E, Christoulas D, Terpos E, Bamias A (2009) Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20:117–120CrossRefPubMed
87.
Zurück zum Zitat Fleisch H, Reszka A, Rodan G, Rogers M (2002) Bisphosphonates: mechanisms of action. In: Bilezikian JP, Raisz LG, Rodan GA (eds) Principles of bone biology, 2nd edn. Academic Press, San Diego, pp 1361–1385 Fleisch H, Reszka A, Rodan G, Rogers M (2002) Bisphosphonates: mechanisms of action. In: Bilezikian JP, Raisz LG, Rodan GA (eds) Principles of bone biology, 2nd edn. Academic Press, San Diego, pp 1361–1385
88.
Zurück zum Zitat Terpos E, Sezer O, Croucher PI, García-Sanz R, Boccadoro M, San Miguel J, Ashcroft J, Bladé J, Cavo M, Delforge M, Dimopoulos MA, Facon T, Macro M, Waage A, Sonneveld P (2009) The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 20:1303–1317CrossRefPubMed Terpos E, Sezer O, Croucher PI, García-Sanz R, Boccadoro M, San Miguel J, Ashcroft J, Bladé J, Cavo M, Delforge M, Dimopoulos MA, Facon T, Macro M, Waage A, Sonneveld P (2009) The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 20:1303–1317CrossRefPubMed
90.
Zurück zum Zitat Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP, Coleman RE (2003) Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 89:2031–2037CrossRefPubMed Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP, Coleman RE (2003) Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 89:2031–2037CrossRefPubMed
91.
Zurück zum Zitat Chahine C, Cheung MS, Head TW, Schwartz S, Glorieux FH, Rauch F (2008) Tooth extraction socket healing in pediatric patients treated with intravenous pamidronate. J Pediatr 153:719–720CrossRefPubMed Chahine C, Cheung MS, Head TW, Schwartz S, Glorieux FH, Rauch F (2008) Tooth extraction socket healing in pediatric patients treated with intravenous pamidronate. J Pediatr 153:719–720CrossRefPubMed
92.
Zurück zum Zitat Malmgren B, Astrom E, Soderhall S (2008) No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates. J Oral Pathol Med 37:196–200PubMedCrossRef Malmgren B, Astrom E, Soderhall S (2008) No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates. J Oral Pathol Med 37:196–200PubMedCrossRef
93.
Zurück zum Zitat Curtis JR, Westfall AO, Cheng H, Delzell E, Saag KG (2008) Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int 19:1613–1620CrossRefPubMed Curtis JR, Westfall AO, Cheng H, Delzell E, Saag KG (2008) Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int 19:1613–1620CrossRefPubMed
94.
Zurück zum Zitat Melo MD, Obeid G (2005) Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition. J Am Dent Assoc 136:1675–1681PubMed Melo MD, Obeid G (2005) Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition. J Am Dent Assoc 136:1675–1681PubMed
95.
Zurück zum Zitat Migliorati CA, Schubert MM, Peterson DE, Seneda LM (2005) Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer (Phila) 104:83–93CrossRef Migliorati CA, Schubert MM, Peterson DE, Seneda LM (2005) Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer (Phila) 104:83–93CrossRef
96.
Zurück zum Zitat Carlson ER, Basile JD (2009) The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 67(5 Suppl):85–95CrossRefPubMed Carlson ER, Basile JD (2009) The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 67(5 Suppl):85–95CrossRefPubMed
97.
Zurück zum Zitat Marx RE (2009) Reconstruction of defects caused by bisphosphonate-induced osteonecrosis of the jaws. J Oral Maxillofac Surg 67(5 Suppl):107–119CrossRefPubMed Marx RE (2009) Reconstruction of defects caused by bisphosphonate-induced osteonecrosis of the jaws. J Oral Maxillofac Surg 67(5 Suppl):107–119CrossRefPubMed
98.
Zurück zum Zitat Freiberger JJ (2009) Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 67(5 Suppl):96–106CrossRefPubMed Freiberger JJ (2009) Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 67(5 Suppl):96–106CrossRefPubMed
99.
Zurück zum Zitat Harper RP, Fung E (2007) Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH (1–34)]. J Oral Maxillofac Surg 65:573–580CrossRefPubMed Harper RP, Fung E (2007) Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH (1–34)]. J Oral Maxillofac Surg 65:573–580CrossRefPubMed
100.
Zurück zum Zitat Timurağaoğlu A, Ozkaynak C, Tuzuner S, Bostan F, Undar L (2007) Improvement of zoledronic-acid-induced jaw osteonecrosis with bortezomib. Acta Haematol 118:203–204CrossRefPubMed Timurağaoğlu A, Ozkaynak C, Tuzuner S, Bostan F, Undar L (2007) Improvement of zoledronic-acid-induced jaw osteonecrosis with bortezomib. Acta Haematol 118:203–204CrossRefPubMed
101.
Zurück zum Zitat Van den Wyngaert T, Claeys T, Huizing MT, Vermorken JB, Fossion E (2009) Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome. Ann Oncol 20:331–336CrossRefPubMed Van den Wyngaert T, Claeys T, Huizing MT, Vermorken JB, Fossion E (2009) Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome. Ann Oncol 20:331–336CrossRefPubMed
102.
Zurück zum Zitat Wimalawansa SJ (2008) Bisphosphonate-associated osteomyelitis of the jaw: guidelines for practicing clinicians. Endocr Pract 14:1150–1168PubMed Wimalawansa SJ (2008) Bisphosphonate-associated osteomyelitis of the jaw: guidelines for practicing clinicians. Endocr Pract 14:1150–1168PubMed
103.
Zurück zum Zitat Taylor KH, Middlefell LS, Mizen KD (2010) Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg (in press) Taylor KH, Middlefell LS, Mizen KD (2010) Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg (in press)
Metadaten
Titel
Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons
verfasst von
Toshiyuki Yoneda
Hiroshi Hagino
Toshitsugu Sugimoto
Hiroaki Ohta
Shunji Takahashi
Satoshi Soen
Akira Taguchi
Satoru Toyosawa
Toshihiko Nagata
Masahiro Urade
Publikationsdatum
01.07.2010
Verlag
Springer Japan
Erschienen in
Journal of Bone and Mineral Metabolism / Ausgabe 4/2010
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-010-0162-7

Weitere Artikel der Ausgabe 4/2010

Journal of Bone and Mineral Metabolism 4/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.